Search for authorsSearch for similar articles
33
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Colorectal cancer is considered one of the major malignancies that threaten the lives and health of people around the world. Patients with CRC are prone to post-operative local recurrence or metastasis, and some patients are advanced at the time of diagnosis and have no chance for complete surgical resection. These factors make chemotherapy an indispensable and important tool in treating CRC. However, the complex composition of the tumor microenvironment and the interaction of cellular and interstitial components constitute a tumor tissue with high cell density, dense extracellular matrix, and high osmotic pressure, inevitably preventing chemotherapeutic drugs from entering and acting on tumor cells. As a result, a novel drug carrier system with targeted nanoparticles has been applied to tumor therapy. It can change the physicochemical properties of drugs, facilitate the crossing of drug molecules through physiological and pathological tissue barriers, and increase the local concentration of nanomedicines at lesion sites. In addition to improving drug efficacy, targeted nanoparticles also reduce side effects, enabling safer and more effective disease diagnosis and treatment and improving bioavailability. In this review, we discuss the mechanisms by which infiltrating cells and other stromal components of the tumor microenvironment comprise barriers to chemotherapy in colorectal cancer. The research and application of targeted nanoparticles in CRC treatment are also classified.

          Related collections

          Most cited references198

          • Record: found
          • Abstract: found
          • Article: found

          Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

          Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer medicine. Here, we review data and technologies that have revealed intra-tumor heterogeneity across cancer types and the dynamics, constraints, and contingencies inherent to tumor evolution. We emphasize the importance of macro-evolutionary leaps, often involving large-scale chromosomal alterations, in driving tumor evolution and metastasis and consider the role of the tumor microenvironment in engendering heterogeneity and drug resistance. We suggest that bold approaches to drug development, harnessing the adaptive properties of the immune-microenvironment while limiting those of the tumor, combined with advances in clinical trial-design, will improve patient outcome.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Immunological hallmarks of stromal cells in the tumour microenvironment.

            A dynamic and mutualistic interaction between tumour cells and the surrounding stroma promotes the initiation, progression, metastasis and chemoresistance of solid tumours. Far less understood is the relationship between the stroma and tumour-infiltrating leukocytes; however, emerging evidence suggests that the stromal compartment can shape antitumour immunity and responsiveness to immunotherapy. Thus, there is growing interest in elucidating the immunomodulatory roles of the stroma that evolve within the tumour microenvironment. In this Review, we discuss the evidence that stromal determinants interact with leukocytes and influence antitumour immunity, with emphasis on the immunological attributes of stromal cells that may foster their protumorigenic function.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Photodynamic therapy – mechanisms, photosensitizers and combinations

              Photodynamic therapy (PDT) is a modern and non-invasive form of therapy, used in the treatment of non-oncological diseases as well as cancers of various types and locations. It is based on the local or systemic application of a photosensitive compound - the photosensitizer, which is accumulated in pathological tissues. The photosensitizer molecules absorb the light of the appropriate wavelength, initiating the activation processes leading to the selective destruction of the inappropriate cells. The photocytotoxic reactions occur only within the pathological tissues, in the area of photosensitizer distribution, enabling selective destruction. Over the last decade, a significant acceleration in the development of nanotechnology has been observed. The combination of photosensitizers with nanomaterials can improve the photodynamic therapy efficiency and eliminate its side effects as well. The use of nanoparticles enables achievement a targeted method which is focused on specific receptors, and, as a result, increases the selectivity of the photodynamic therapy. The object of this review is the anticancer application of PDT, its advantages and possible modifications to potentiate its effects.
                Bookmark

                Author and article information

                Contributors
                guoyu126344@163.com
                jdeywangmin@163.com
                373111984@qq.com
                jinlonghai@jlu.edu.cn
                dearzhaoyun@163.com
                499727901@qq.com
                jdeywangshuang@163.com
                jnli@ciac.ac.cn
                Journal
                J Nanobiotechnology
                J Nanobiotechnology
                Journal of Nanobiotechnology
                BioMed Central (London )
                1477-3155
                11 August 2022
                11 August 2022
                2022
                : 20
                : 371
                Affiliations
                [1 ]GRID grid.64924.3d, ISNI 0000 0004 1760 5735, Department of the General Surgery, , Jilin University Second Hospital, ; Changchun, 130000 China
                [2 ]GRID grid.64924.3d, ISNI 0000 0004 1760 5735, Department of Radiology, , Jilin University Second Hospital, ; Changchun, 130000 China
                [3 ]GRID grid.64924.3d, ISNI 0000 0004 1760 5735, Department of the Dermatology, , Jilin University Second Hospital, ; Changchun, 130000 China
                Article
                1586
                10.1186/s12951-022-01586-4
                9367166
                35953863
                a36eac3a-0ac6-4390-baa1-3f508f2cf8b8
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 31 May 2022
                : 4 August 2022
                Funding
                Funded by: National Natural Science Foundation of China
                Award ID: No. 32000953
                Award Recipient :
                Funded by: Science and Technology Department of Jilin Province
                Award ID: No. YDZJ202201ZYTS004
                Award Recipient :
                Funded by: Financial Department of Jilin Province
                Award ID: No. 2019SCZT045
                Award Recipient :
                Funded by: Education Project of Jilin University
                Award ID: #419070600046 and 45121031D024
                Award Recipient :
                Categories
                Review
                Custom metadata
                © The Author(s) 2022

                Biotechnology
                colorectal cancer,targeted nanoparticles,chemotherapeutic resistance
                Biotechnology
                colorectal cancer, targeted nanoparticles, chemotherapeutic resistance

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content700

                Cited by20

                Most referenced authors2,542